Advertisement

Topics

Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500

13:01 EDT 14 Mar 2018 | BioPortfolio Report Blog

Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 Pipeline Review, H1 2018


Summary


According to the recently published report 'Histamine H4 Receptor Pipeline Review, H1 2018'; Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies.


Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 The histamine H4 receptor is a member of the G proteincoupled receptor super family.


H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histaminemediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.


The report 'Histamine H4 Receptor Pipeline Review, H1 2018' outlays comprehensive information on the Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 7 and 1 respectively.


Report covers products from therapy areas Immunology, Ear Nose Throat Disorders, Ophthalmology, Respiratory and Dermatology which include indications Allergic Conjunctivitis, Plaque Psoriasis Psoriasis Vulgaris, Acute Sensorineural Hearing Loss, Allergies, Asthma, Atopic Dermatitis, Cystic Fibrosis, Hearing Disorders, Idiopathic Pulmonary Fibrosis, Inflammation, Rheumatoid Arthritis, RhinoConjunctivitis, Vertigo, Vestibular Diseases and Vestibular Neuronitis.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4

The report reviews Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics and enlists all their major and minor projects

The report assesses Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...